Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial
Background - The primary objective of this study is to evaluate the clinical significance of RANK/L expression, in both a retrospective cohort of surgically resected stage I-III NSCLC (Lungscape) and a randomized clinical trial-cohort (SPLENDOUR) of advanced NSCLC treated with chemotherapy alone or...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
January 2023
|
| In: |
Lung cancer
Year: 2023, Jahrgang: 175, Pages: 141-151 |
| ISSN: | 1872-8332 |
| DOI: | 10.1016/j.lungcan.2022.12.004 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.lungcan.2022.12.004 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0169500222007139 
|
| Verfasserangaben: | Solange Peters, Igor Letovanec, Murielle Mauer, Urania Dafni, Dunson Ejedepang, Wojciech Biernat, Lukas Bubendorf, Arne Warth, Saraswati Pokharel, Niels Reinmuth, Margarita Majem Tarruella, Jose Casas-Martin, Zoi Tsourti, Nesa Marti, Roswitha Kammler, Sarah Danson, Mary O'Brien, Rolf. A. Stahel |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1851102140 | ||
| 003 | DE-627 | ||
| 005 | 20240328080730.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230627s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2022.12.004 |2 doi | |
| 035 | |a (DE-627)1851102140 | ||
| 035 | |a (DE-599)KXP1851102140 | ||
| 035 | |a (OCoLC)1389527997 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Peters, Solange |d 1972- |e VerfasserIn |0 (DE-588)113195274X |0 (DE-627)887311555 |0 (DE-576)488580404 |4 aut | |
| 245 | 1 | 0 | |a Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial |c Solange Peters, Igor Letovanec, Murielle Mauer, Urania Dafni, Dunson Ejedepang, Wojciech Biernat, Lukas Bubendorf, Arne Warth, Saraswati Pokharel, Niels Reinmuth, Margarita Majem Tarruella, Jose Casas-Martin, Zoi Tsourti, Nesa Marti, Roswitha Kammler, Sarah Danson, Mary O'Brien, Rolf. A. Stahel |
| 264 | 1 | |c January 2023 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Published: 13 December 2022 | ||
| 500 | |a Gesehen am 27.06.2023 | ||
| 520 | |a Background - The primary objective of this study is to evaluate the clinical significance of RANK/L expression, in both a retrospective cohort of surgically resected stage I-III NSCLC (Lungscape) and a randomized clinical trial-cohort (SPLENDOUR) of advanced NSCLC treated with chemotherapy alone or in combination with denosumab. - Methods - RANK-L expression was assessed on tissue microarrays (TMAs) in Lungscape and whole sections in SPLENDOUR, using immunohistochemistry, with H-scores values > 0 indicating positivity. Prevalence of RANK positivity and its association with clinicopathological characteristics, and patient outcome was explored in a subset of the ETOP Lungscape cohort and in SPLENDOUR. Also investigated were the prevalence of RANK overexpression (proportion of positive cancer cells ≥ 50%) in the Lungscape cohort, and RANK-L in the SPLENDOUR trial. - Results - In the Lungscape cohort, RANK expression was assessed at a median follow-up of 46 months (N = 488 patients; 4 centers); 35% were female, 44/49/6% adenocarcinomas (AC)/squamous cell carcinomas (SCC)/other, 48/27/25% with stage I/II/III. Median RFS/TTR/OS were 58/Not reached/74 months. Prevalence of RANK expression was 31% (95%CI:27%-35%); significantly higher in AC: 50% (95%CI:43%-57%) vs SCC: 12% (95%CI:8%-16%) (p < 0.001); more frequent in females (42% vs 25%, p < 0.001) and tumors ≤ 4 cm (35.3% vs 23.3%, p = 0.0065). No association with outcome was found. In the SPLENDOUR trial (463 patients), the prevalence of membranous and cytoplasmic RANK positivity was 34% (95%CI:30%-38%) and 9% (95%CI:7%-12%), respectively, while prevalence for RANK-L was 5% (95%CI:3%-7%) and 36% (95%CI:31%-40%), respectively. Cytoplasmic RANK-L positivity was more common among females (47% vs 31%, p = 0.001) and in non-SCC histology (45% vs 10%, p < 0.0001). At the pre-specified 1% significance level, no prognostic or predictive effect was found. - Conclusions - Both cohorts indicate that RANK expression is more common in adenocarcinoma/non-squamous NSCLC and in female patients. No prognostic effect is found, and in the clinical trial involving addition of denosumab to chemotherapy no predictive effect is detected. | ||
| 650 | 4 | |a Denosumab | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a RANK | |
| 650 | 4 | |a RANKL | |
| 700 | 1 | |a Letovanec, Igor |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mauer, Murielle |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dafni, Urania |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ejedepang, Dunson |e VerfasserIn |4 aut | |
| 700 | 1 | |a Biernat, Wojciech |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bubendorf, Lukas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Warth, Arne |d 1979- |e VerfasserIn |0 (DE-588)132646145 |0 (DE-627)524716927 |0 (DE-576)260019755 |4 aut | |
| 700 | 1 | |a Pokharel, Saraswati |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reinmuth, Niels |e VerfasserIn |4 aut | |
| 700 | 1 | |a Majem Tarruella, Margarita |e VerfasserIn |4 aut | |
| 700 | 1 | |a Casas-Martin, Jose |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tsourti, Zoi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marti, Nesa |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kammler, Roswitha |e VerfasserIn |4 aut | |
| 700 | 1 | |a Danson, Sarah |e VerfasserIn |4 aut | |
| 700 | 1 | |a O'Brien, Mary |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stahel, Rolf A. |d 1950- |e VerfasserIn |0 (DE-588)1089132557 |0 (DE-627)851011160 |0 (DE-576)459906275 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer |d Amsterdam [u.a.] : Elsevier, 1985 |g 175(2023), Seite 141-151 |h Online-Ressource |w (DE-627)320649733 |w (DE-600)2025812-4 |w (DE-576)264627539 |x 1872-8332 |7 nnas |a Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial |
| 773 | 1 | 8 | |g volume:175 |g year:2023 |g pages:141-151 |g extent:11 |a Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.lungcan.2022.12.004 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0169500222007139 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230627 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 132646145 |a Warth, Arne |m 132646145:Warth, Arne |d 50000 |e 50000PW132646145 |k 0/50000/ |p 8 | ||
| 999 | |a KXP-PPN1851102140 |e 4343992152 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Published: 13 December 2022","Gesehen am 27.06.2023"],"recId":"1851102140","language":["eng"],"person":[{"role":"aut","roleDisplay":"VerfasserIn","display":"Peters, Solange","given":"Solange","family":"Peters"},{"display":"Letovanec, Igor","roleDisplay":"VerfasserIn","role":"aut","family":"Letovanec","given":"Igor"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Mauer, Murielle","given":"Murielle","family":"Mauer"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Dafni, Urania","given":"Urania","family":"Dafni"},{"role":"aut","display":"Ejedepang, Dunson","roleDisplay":"VerfasserIn","given":"Dunson","family":"Ejedepang"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Biernat, Wojciech","given":"Wojciech","family":"Biernat"},{"given":"Lukas","family":"Bubendorf","role":"aut","display":"Bubendorf, Lukas","roleDisplay":"VerfasserIn"},{"family":"Warth","given":"Arne","roleDisplay":"VerfasserIn","display":"Warth, Arne","role":"aut"},{"display":"Pokharel, Saraswati","roleDisplay":"VerfasserIn","role":"aut","family":"Pokharel","given":"Saraswati"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Reinmuth, Niels","given":"Niels","family":"Reinmuth"},{"roleDisplay":"VerfasserIn","display":"Majem Tarruella, Margarita","role":"aut","family":"Majem Tarruella","given":"Margarita"},{"family":"Casas-Martin","given":"Jose","roleDisplay":"VerfasserIn","display":"Casas-Martin, Jose","role":"aut"},{"role":"aut","display":"Tsourti, Zoi","roleDisplay":"VerfasserIn","given":"Zoi","family":"Tsourti"},{"family":"Marti","given":"Nesa","display":"Marti, Nesa","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Kammler, Roswitha","role":"aut","family":"Kammler","given":"Roswitha"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Danson, Sarah","given":"Sarah","family":"Danson"},{"given":"Mary","family":"O'Brien","role":"aut","roleDisplay":"VerfasserIn","display":"O'Brien, Mary"},{"given":"Rolf A.","family":"Stahel","role":"aut","display":"Stahel, Rolf A.","roleDisplay":"VerfasserIn"}],"title":[{"title_sort":"Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial","title":"Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trial"}],"physDesc":[{"extent":"11 S."}],"relHost":[{"pubHistory":["1.1985 -"],"part":{"pages":"141-151","year":"2023","extent":"11","text":"175(2023), Seite 141-151","volume":"175"},"disp":"Assessment of RANK/RANK-L prevalence and clinical significance in NSCLC European Thoracic Oncology Platform Lungscape cohort and SPLENDOUR randomized clinical trialLung cancer","note":["Gesehen am 20.02.20"],"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"320649733","language":["eng"],"title":[{"subtitle":"journal of the International Association for the Study of Lung Cancer","title":"Lung cancer","title_sort":"Lung cancer"}],"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"dateIssuedKey":"1985","publisher":"Elsevier","dateIssuedDisp":"1985-","publisherPlace":"Amsterdam [u.a.]"}],"id":{"issn":["1872-8332"],"eki":["320649733"],"zdb":["2025812-4"]}}],"name":{"displayForm":["Solange Peters, Igor Letovanec, Murielle Mauer, Urania Dafni, Dunson Ejedepang, Wojciech Biernat, Lukas Bubendorf, Arne Warth, Saraswati Pokharel, Niels Reinmuth, Margarita Majem Tarruella, Jose Casas-Martin, Zoi Tsourti, Nesa Marti, Roswitha Kammler, Sarah Danson, Mary O'Brien, Rolf. A. Stahel"]},"origin":[{"dateIssuedDisp":"January 2023","dateIssuedKey":"2023"}],"id":{"doi":["10.1016/j.lungcan.2022.12.004"],"eki":["1851102140"]}} | ||
| SRT | |a PETERSSOLAASSESSMENT2023 | ||